Lappe Mark's Form 4 filing
Inhibrx Biosciences, Inc. (INBX) · filed Sep 28, 2026
- Accession no.
- 0001366074-26-000004
- Filed
- Sep 28, 2026, 5:47 PM ET
- Trade date
- Sep 25-28, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $998.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lappe MarkCIK 0001366074 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Common Stock | PPurchaseAcquired | +3,324 | $98.87F1 | +$328,630.25 | 733,872 | Indirect | |
| Sep 25, 2026 | Common Stock | PPurchaseAcquired | +2,176 | $99.60F3 | +$216,726.99 | 736,048 | Indirect | |
| Sep 28, 2026 | Common Stock | PPurchaseAcquired | +1,500 | $98.88F4 | +$148,320.45 | 737,548 | Indirect | |
| Sep 28, 2026 | Common Stock | PPurchaseAcquired | +3,000 | $101.70F5 | +$305,106 | 740,548 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were purchased in multiple transactions at prices ranging from $98.27 to $99.26 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were purchased in multiple transactions at prices ranging from $99.335 to $100.00 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were purchased in multiple transactions at prices ranging from $98.69 to $99.21 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F5
The shares were purchased in multiple transactions at prices ranging from $101.44 to $101.80 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.